Chronic graft-versus-host disease after allogeneic blood stem cell transplantation

Donna Przepiorka, Paolo Anderlini, Rima Saliba, Karen Cleary, Rakesh Mehra, Issa Khouri, Yang O. Huh, Sergio Giralt, Ira Braunschweig, Koen Van Besien, Richard Champlin

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

The incidence, characteristics, risk factors for, and impact of chronic graft-vs-host disease (GVHD) were evaluated in a consecutive series of 116 evaluable HLA-identical blood stem cell transplant recipients. Minimum follow-up was 18 months. Limited chronic GVHD occurred in 6% (95% confidence interval [CI], 0%-13%), and clinical extensive chronic GVHD in 71% (95% CI, 61%-80%). The cumulative incidence was 57% (95% CI, 48%-66%). In univariate analyses, GVHD prophylaxis other than tacrolimus and methotrexate, prior grades 2 to 4 acute GVHD, use of corticosteroids on day 100, and total nucleated cell dose were significant risk factors for clinical extensive chronic GVHD. On multivariate analysis, GVHD prophylaxis with tacrolimus and methotrexate was associated with a reduced risk of chronic GVHD (hazard ratio [HR], 0.35; P = .001), whereas the risk was increased with prior acute GVHD (HR, 1.67; P = .046). When adjusted for disease status at the time of transplantation, high-risk chronic GVHD had an adverse impact on overall mortality (HR, 6.6; P < .001) and treatment failure (HR, 5.2; P < .001) at 18 months. It was concluded that there is a substantial rate of chronic GVHD after HLA-identical allogeneic blood stem cell transplantation, that clinical factors may alter the risk of chronic GVHD, and that high-risk chronic GVHD adversely affects outcome.

Original languageEnglish (US)
Pages (from-to)1695-1700
Number of pages6
JournalBlood
Volume98
Issue number6
DOIs
StatePublished - Sep 15 2001
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Graft vs Host Disease
Stem cells
Grafts
Blood Cells
Blood
Hazards
Transplantation (surgical)
Tacrolimus
Confidence Intervals
Methotrexate
Transplants
Incidence
Treatment Failure
Adrenal Cortex Hormones
Stem Cells
Multivariate Analysis
Transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Przepiorka, D., Anderlini, P., Saliba, R., Cleary, K., Mehra, R., Khouri, I., ... Champlin, R. (2001). Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood, 98(6), 1695-1700. https://doi.org/10.1182/blood.V98.6.1695

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. / Przepiorka, Donna; Anderlini, Paolo; Saliba, Rima; Cleary, Karen; Mehra, Rakesh; Khouri, Issa; Huh, Yang O.; Giralt, Sergio; Braunschweig, Ira; Van Besien, Koen; Champlin, Richard.

In: Blood, Vol. 98, No. 6, 15.09.2001, p. 1695-1700.

Research output: Contribution to journalArticle

Przepiorka, D, Anderlini, P, Saliba, R, Cleary, K, Mehra, R, Khouri, I, Huh, YO, Giralt, S, Braunschweig, I, Van Besien, K & Champlin, R 2001, 'Chronic graft-versus-host disease after allogeneic blood stem cell transplantation', Blood, vol. 98, no. 6, pp. 1695-1700. https://doi.org/10.1182/blood.V98.6.1695
Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001 Sep 15;98(6):1695-1700. https://doi.org/10.1182/blood.V98.6.1695
Przepiorka, Donna ; Anderlini, Paolo ; Saliba, Rima ; Cleary, Karen ; Mehra, Rakesh ; Khouri, Issa ; Huh, Yang O. ; Giralt, Sergio ; Braunschweig, Ira ; Van Besien, Koen ; Champlin, Richard. / Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. In: Blood. 2001 ; Vol. 98, No. 6. pp. 1695-1700.
@article{68d22248d77040acbdc135461eaf563c,
title = "Chronic graft-versus-host disease after allogeneic blood stem cell transplantation",
abstract = "The incidence, characteristics, risk factors for, and impact of chronic graft-vs-host disease (GVHD) were evaluated in a consecutive series of 116 evaluable HLA-identical blood stem cell transplant recipients. Minimum follow-up was 18 months. Limited chronic GVHD occurred in 6{\%} (95{\%} confidence interval [CI], 0{\%}-13{\%}), and clinical extensive chronic GVHD in 71{\%} (95{\%} CI, 61{\%}-80{\%}). The cumulative incidence was 57{\%} (95{\%} CI, 48{\%}-66{\%}). In univariate analyses, GVHD prophylaxis other than tacrolimus and methotrexate, prior grades 2 to 4 acute GVHD, use of corticosteroids on day 100, and total nucleated cell dose were significant risk factors for clinical extensive chronic GVHD. On multivariate analysis, GVHD prophylaxis with tacrolimus and methotrexate was associated with a reduced risk of chronic GVHD (hazard ratio [HR], 0.35; P = .001), whereas the risk was increased with prior acute GVHD (HR, 1.67; P = .046). When adjusted for disease status at the time of transplantation, high-risk chronic GVHD had an adverse impact on overall mortality (HR, 6.6; P < .001) and treatment failure (HR, 5.2; P < .001) at 18 months. It was concluded that there is a substantial rate of chronic GVHD after HLA-identical allogeneic blood stem cell transplantation, that clinical factors may alter the risk of chronic GVHD, and that high-risk chronic GVHD adversely affects outcome.",
author = "Donna Przepiorka and Paolo Anderlini and Rima Saliba and Karen Cleary and Rakesh Mehra and Issa Khouri and Huh, {Yang O.} and Sergio Giralt and Ira Braunschweig and {Van Besien}, Koen and Richard Champlin",
year = "2001",
month = "9",
day = "15",
doi = "10.1182/blood.V98.6.1695",
language = "English (US)",
volume = "98",
pages = "1695--1700",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Chronic graft-versus-host disease after allogeneic blood stem cell transplantation

AU - Przepiorka, Donna

AU - Anderlini, Paolo

AU - Saliba, Rima

AU - Cleary, Karen

AU - Mehra, Rakesh

AU - Khouri, Issa

AU - Huh, Yang O.

AU - Giralt, Sergio

AU - Braunschweig, Ira

AU - Van Besien, Koen

AU - Champlin, Richard

PY - 2001/9/15

Y1 - 2001/9/15

N2 - The incidence, characteristics, risk factors for, and impact of chronic graft-vs-host disease (GVHD) were evaluated in a consecutive series of 116 evaluable HLA-identical blood stem cell transplant recipients. Minimum follow-up was 18 months. Limited chronic GVHD occurred in 6% (95% confidence interval [CI], 0%-13%), and clinical extensive chronic GVHD in 71% (95% CI, 61%-80%). The cumulative incidence was 57% (95% CI, 48%-66%). In univariate analyses, GVHD prophylaxis other than tacrolimus and methotrexate, prior grades 2 to 4 acute GVHD, use of corticosteroids on day 100, and total nucleated cell dose were significant risk factors for clinical extensive chronic GVHD. On multivariate analysis, GVHD prophylaxis with tacrolimus and methotrexate was associated with a reduced risk of chronic GVHD (hazard ratio [HR], 0.35; P = .001), whereas the risk was increased with prior acute GVHD (HR, 1.67; P = .046). When adjusted for disease status at the time of transplantation, high-risk chronic GVHD had an adverse impact on overall mortality (HR, 6.6; P < .001) and treatment failure (HR, 5.2; P < .001) at 18 months. It was concluded that there is a substantial rate of chronic GVHD after HLA-identical allogeneic blood stem cell transplantation, that clinical factors may alter the risk of chronic GVHD, and that high-risk chronic GVHD adversely affects outcome.

AB - The incidence, characteristics, risk factors for, and impact of chronic graft-vs-host disease (GVHD) were evaluated in a consecutive series of 116 evaluable HLA-identical blood stem cell transplant recipients. Minimum follow-up was 18 months. Limited chronic GVHD occurred in 6% (95% confidence interval [CI], 0%-13%), and clinical extensive chronic GVHD in 71% (95% CI, 61%-80%). The cumulative incidence was 57% (95% CI, 48%-66%). In univariate analyses, GVHD prophylaxis other than tacrolimus and methotrexate, prior grades 2 to 4 acute GVHD, use of corticosteroids on day 100, and total nucleated cell dose were significant risk factors for clinical extensive chronic GVHD. On multivariate analysis, GVHD prophylaxis with tacrolimus and methotrexate was associated with a reduced risk of chronic GVHD (hazard ratio [HR], 0.35; P = .001), whereas the risk was increased with prior acute GVHD (HR, 1.67; P = .046). When adjusted for disease status at the time of transplantation, high-risk chronic GVHD had an adverse impact on overall mortality (HR, 6.6; P < .001) and treatment failure (HR, 5.2; P < .001) at 18 months. It was concluded that there is a substantial rate of chronic GVHD after HLA-identical allogeneic blood stem cell transplantation, that clinical factors may alter the risk of chronic GVHD, and that high-risk chronic GVHD adversely affects outcome.

UR - http://www.scopus.com/inward/record.url?scp=0035885921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035885921&partnerID=8YFLogxK

U2 - 10.1182/blood.V98.6.1695

DO - 10.1182/blood.V98.6.1695

M3 - Article

C2 - 11535499

AN - SCOPUS:0035885921

VL - 98

SP - 1695

EP - 1700

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -